首页 > 最新文献

Frontiers in allergy最新文献

英文 中文
House dust mite sublingual allergen immunotherapy tablet is safe and well-tolerated in Dutch clinical practice. 在荷兰的临床实践中,屋尘螨舌下过敏原免疫疗法片剂安全且耐受性良好。
Q2 ALLERGY Pub Date : 2024-02-29 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1355324
Žana Tempels-Pavlica, Mark C J Aarts, Paco M J Welsing, Akke-Nynke van der Meer, Leonard P van der Zwan, Elena Uss, André C Knulst

Background: Half (49%) of clinically diagnosed allergic rhinitis (AR) patients are sensitized to house dust mite (HDM). If allergen avoidance and symptomatic medication fail, allergen immunotherapy may be indicated.

Objective: We investigated safety and tolerability of HDM-sublingual immunotherapy by HDM-SLIT tablets in Dutch daily clinical practice.

Methods: Daily intake of 12 SQ-HDM SLIT-tablet was investigated in a prospective, multicenter, observational study (EUPAS43753). It comprised 4 consultations in 1 year. Data on safety, tolerability, treatment satisfaction, symptomatic medication, compliance, and clinical effectiveness (Control of Allergic Rhinitis and Asthma Test; CARAT) were collected. Descriptive and longitudinal regression data analysis were performed.

Results: Adult patients (n = 415), mean (SD) age 36.6 (12.2) years, 61.4% female and 36% asthmatic were included. The preponderance (65.1%) experienced adverse events (AEs). These, mostly mild (67%), AEs comprised: oral allergic reactions (58.6%), respiratory (12.4%) and gastrointestinal symptoms (9.4%). Sixty (14.5%) patients stopped due to AEs and 76 (18.3%) for non-AE reasons. CARAT scores improved clinically significant by 6 points and symptomatic medication use decreased from 96.1% to 77.4%. Most patients (74.5%) tolerated the treatment and were compliant (>86.5%). The majority of patients (62.4%) and investigators (69.4%) were satisfied with treatment.

Conclusions: HDM SLIT-tablet is a safe and well-tolerated AR treatment. AEs occur often but are mostly mild and decreasing during the first year. CARAT scores improved and symptomatic medication use decreased suggesting better control of AR with treatment. Compliance, tolerability, and treatment satisfaction are good. However, patient follow-up and compliance remain important points of attention when initiating treatment.

背景:在临床诊断的过敏性鼻炎(AR)患者中,有一半(49%)对屋尘螨(HDM)过敏。如果避开过敏原和对症药物治疗无效,可能需要进行过敏原免疫治疗:我们调查了荷兰日常临床实践中使用 HDM-SLIT 片剂进行 HDM 舌下免疫疗法的安全性和耐受性:在一项前瞻性、多中心、观察性研究(EUPAS43753)中,对每天摄入 12 片 SQ-HDM SLIT 片剂进行了调查。该研究为期一年,共进行了 4 次问诊。研究收集了有关安全性、耐受性、治疗满意度、对症用药、依从性和临床效果(过敏性鼻炎和哮喘控制测试;CARAT)的数据。对数据进行了描述性分析和纵向回归分析:成年患者(n = 415),平均(标清)年龄为 36.6(12.2)岁,61.4% 为女性,36% 为哮喘患者。大多数患者(65.1%)出现了不良反应(AEs)。这些不良反应大多较轻(67%),包括:口腔过敏反应(58.6%)、呼吸道症状(12.4%)和胃肠道症状(9.4%)。有 60 名患者(14.5%)因过敏反应而停药,76 名患者(18.3%)因非过敏反应原因而停药。CARAT 评分在临床上显著提高了 6 分,无症状药物使用率从 96.1% 降至 77.4%。大多数患者(74.5%)都能耐受治疗,并遵从医嘱(>86.5%)。大多数患者(62.4%)和调查人员(69.4%)对治疗表示满意:结论:HDM SLIT片剂是一种安全且耐受性良好的AR治疗药物。结论:HDM SLIT 片剂是一种安全且耐受性良好的 AR 治疗药物,其不良反应经常发生,但大多较轻,且在第一年内逐渐减少。CARAT 评分有所提高,症状性用药减少,这表明通过治疗可以更好地控制 AR。依从性、耐受性和治疗满意度都很好。不过,在开始治疗时,患者的随访和依从性仍是重要的注意事项。
{"title":"House dust mite sublingual allergen immunotherapy tablet is safe and well-tolerated in Dutch clinical practice.","authors":"Žana Tempels-Pavlica, Mark C J Aarts, Paco M J Welsing, Akke-Nynke van der Meer, Leonard P van der Zwan, Elena Uss, André C Knulst","doi":"10.3389/falgy.2024.1355324","DOIUrl":"10.3389/falgy.2024.1355324","url":null,"abstract":"<p><strong>Background: </strong>Half (49%) of clinically diagnosed allergic rhinitis (AR) patients are sensitized to house dust mite (HDM). If allergen avoidance and symptomatic medication fail, allergen immunotherapy may be indicated.</p><p><strong>Objective: </strong>We investigated safety and tolerability of HDM-sublingual immunotherapy by HDM-SLIT tablets in Dutch daily clinical practice.</p><p><strong>Methods: </strong>Daily intake of 12 SQ-HDM SLIT-tablet was investigated in a prospective, multicenter, observational study (EUPAS43753). It comprised 4 consultations in 1 year. Data on safety, tolerability, treatment satisfaction, symptomatic medication, compliance, and clinical effectiveness (Control of Allergic Rhinitis and Asthma Test; CARAT) were collected. Descriptive and longitudinal regression data analysis were performed.</p><p><strong>Results: </strong>Adult patients (<i>n</i> = 415), mean (SD) age 36.6 (12.2) years, 61.4% female and 36% asthmatic were included. The preponderance (65.1%) experienced adverse events (AEs). These, mostly mild (67%), AEs comprised: oral allergic reactions (58.6%), respiratory (12.4%) and gastrointestinal symptoms (9.4%). Sixty (14.5%) patients stopped due to AEs and 76 (18.3%) for non-AE reasons. CARAT scores improved clinically significant by 6 points and symptomatic medication use decreased from 96.1% to 77.4%. Most patients (74.5%) tolerated the treatment and were compliant (>86.5%). The majority of patients (62.4%) and investigators (69.4%) were satisfied with treatment.</p><p><strong>Conclusions: </strong>HDM SLIT-tablet is a safe and well-tolerated AR treatment. AEs occur often but are mostly mild and decreasing during the first year. CARAT scores improved and symptomatic medication use decreased suggesting better control of AR with treatment. Compliance, tolerability, and treatment satisfaction are good. However, patient follow-up and compliance remain important points of attention when initiating treatment.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1355324"},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10937523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140133442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Navigating formula shortages: associations of parental perspectives on transitioning to alternative infant formulas for cow's milk protein allergy during the 2022 national formula shortage. 更正:驾驭配方奶粉短缺:在 2022 年全国配方奶粉短缺期间,父母对过渡到替代婴儿配方奶粉以治疗牛奶蛋白过敏症的看法。
Q2 ALLERGY Pub Date : 2024-02-28 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1380490
Abigail L Fabbrini, Andrew A Farrar, Jerry M Brown, Lea V Oliveros, Jared Florio, Jesse Beacker, Luke Lamos, Jessica V Baran, Michael J Wilsey

[This corrects the article DOI: 10.3389/falgy.2023.1333570.].

[此处更正了文章 DOI:10.3389/falgy.2023.1333570]。
{"title":"Corrigendum: Navigating formula shortages: associations of parental perspectives on transitioning to alternative infant formulas for cow's milk protein allergy during the 2022 national formula shortage.","authors":"Abigail L Fabbrini, Andrew A Farrar, Jerry M Brown, Lea V Oliveros, Jared Florio, Jesse Beacker, Luke Lamos, Jessica V Baran, Michael J Wilsey","doi":"10.3389/falgy.2024.1380490","DOIUrl":"https://doi.org/10.3389/falgy.2024.1380490","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/falgy.2023.1333570.].</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1380490"},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10933096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140121528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allergy-associated biomarkers in early life identified by Omics techniques. 利用 Omics 技术识别生命早期的过敏相关生物标志物。
Q2 ALLERGY Pub Date : 2024-02-23 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1359142
Elisa Zubeldia-Varela, María Dolores Ibáñez-Sandín, Cristina Gomez-Casado, Marina Pérez-Gordo

The prevalence and severity of allergic diseases have increased over the last 30 years. Understanding the mechanisms responsible for these diseases is a major challenge in current allergology, as it is crucial for the transition towards precision medicine, which encompasses predictive, preventive, and personalized strategies. The urge to identify predictive biomarkers of allergy at early stages of life is crucial, especially in the context of major allergic diseases such as food allergy and atopic dermatitis. Identifying these biomarkers could enhance our understanding of the immature immune responses, improve allergy handling at early ages and pave the way for preventive and therapeutic approaches. This minireview aims to explore the relevance of three biomarker categories (proteome, microbiome, and metabolome) in early life. First, levels of some proteins emerge as potential indicators of mucosal health and metabolic status in certain allergic diseases. Second, bacterial taxonomy provides insight into the composition of the microbiota through high-throughput sequencing methods. Finally, metabolites, representing the end products of bacterial and host metabolic activity, serve as early indicators of changes in microbiota and host metabolism. This information could help to develop an extensive identification of biomarkers in AD and FA and their potential in translational personalized medicine in early life.

在过去的 30 年里,过敏性疾病的发病率和严重程度都有所上升。了解这些疾病的发病机制是当前过敏学面临的一项重大挑战,因为这对于向精准医学(包括预测、预防和个性化策略)过渡至关重要。在生命的早期阶段确定过敏的预测性生物标志物至关重要,尤其是在食物过敏和特应性皮炎等主要过敏性疾病方面。确定这些生物标志物可以加深我们对未成熟免疫反应的了解,改善早期过敏的处理,并为预防和治疗方法铺平道路。本微综述旨在探讨生命早期三类生物标志物(蛋白质组、微生物组和代谢组)的相关性。首先,在某些过敏性疾病中,一些蛋白质的水平可作为粘膜健康和代谢状态的潜在指标。其次,细菌分类法通过高通量测序方法提供了对微生物群组成的深入了解。最后,代谢物代表细菌和宿主代谢活动的最终产物,是微生物群和宿主代谢变化的早期指标。这些信息有助于广泛鉴定注意力缺失症和注意力缺失症的生物标志物及其在生命早期个性化医学转化中的潜力。
{"title":"Allergy-associated biomarkers in early life identified by Omics techniques.","authors":"Elisa Zubeldia-Varela, María Dolores Ibáñez-Sandín, Cristina Gomez-Casado, Marina Pérez-Gordo","doi":"10.3389/falgy.2024.1359142","DOIUrl":"10.3389/falgy.2024.1359142","url":null,"abstract":"<p><p>The prevalence and severity of allergic diseases have increased over the last 30 years. Understanding the mechanisms responsible for these diseases is a major challenge in current allergology, as it is crucial for the transition towards precision medicine, which encompasses predictive, preventive, and personalized strategies. The urge to identify predictive biomarkers of allergy at early stages of life is crucial, especially in the context of major allergic diseases such as food allergy and atopic dermatitis. Identifying these biomarkers could enhance our understanding of the immature immune responses, improve allergy handling at early ages and pave the way for preventive and therapeutic approaches. This minireview aims to explore the relevance of three biomarker categories (proteome, microbiome, and metabolome) in early life. First, levels of some proteins emerge as potential indicators of mucosal health and metabolic status in certain allergic diseases. Second, bacterial taxonomy provides insight into the composition of the microbiota through high-throughput sequencing methods. Finally, metabolites, representing the end products of bacterial and host metabolic activity, serve as early indicators of changes in microbiota and host metabolism. This information could help to develop an extensive identification of biomarkers in AD and FA and their potential in translational personalized medicine in early life.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1359142"},"PeriodicalIF":0.0,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10920277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Advances and potential of omics studies for understanding the development of food allergy. 更正:了解食物过敏症发展的omics研究进展和潜力。
Q2 ALLERGY Pub Date : 2024-02-23 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1373485
Sayantani B Sindher, Andrew R Chin, Nima Aghaeepour, Lawrence Prince, Holden Maecker, Gary M Shaw, David Stevenson, Kari C Nadeau, Michael Snyder, Purvesh Khatri, Scott D Boyd, Virginia D Winn, Martin S Angst, R Sharon Chinthrajah

[This corrects the article DOI: 10.3389/falgy.2023.1149008.].

[此处更正文章 DOI:10.3389/falgy.2023.1149008]。
{"title":"Corrigendum: Advances and potential of omics studies for understanding the development of food allergy.","authors":"Sayantani B Sindher, Andrew R Chin, Nima Aghaeepour, Lawrence Prince, Holden Maecker, Gary M Shaw, David Stevenson, Kari C Nadeau, Michael Snyder, Purvesh Khatri, Scott D Boyd, Virginia D Winn, Martin S Angst, R Sharon Chinthrajah","doi":"10.3389/falgy.2024.1373485","DOIUrl":"https://doi.org/10.3389/falgy.2024.1373485","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/falgy.2023.1149008.].</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1373485"},"PeriodicalIF":0.0,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10921899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research gaps and future needs for allergen prediction in food safety. 食品安全中过敏原预测的研究空白和未来需求。
Q2 ALLERGY Pub Date : 2024-02-19 eCollection Date: 2024-01-01 DOI: 10.3389/falgy.2024.1297547
A Fernandez, E Danisman, M Taheri Boroujerdi, S Kazemi, F J Moreno, M M Epstein

The allergenicity and protein risk assessments in food safety are facing new challenges. Demands for healthier and more sustainable food systems have led to significant advances in biotechnology, the development of more complex foods, and the search for alternative protein sources. All this has increased the pressure on the safety assessment prediction approaches anchored into requirements defined in the late 90's. In 2022, the EFSA's Panel on Genetically Modified Organisms published a scientific opinion focusing on the developments needed for allergenicity and protein safety assessments of new products derived from biotechnology. Here, we further elaborate on the main elements described in this scientific opinion and prioritize those development needs requiring critical attention. The starting point of any new recommendation would require a focus on clinical relevance and the development of a fit-for-purpose database targeted for specific risk assessment goals. Furthermore, it is imperative to review and clarify the main purpose of the allergenicity risk assessment. An internationally agreed consensus on the overall purpose of allergenicity risk assessment will accelerate the development of fit-for-purpose methodologies, where the role of exposure should be better clarified. Considering the experience gained over the last 25 years and recent scientific developments in the fields of biotechnology, allergy, and risk assessment, it is time to revise and improve the allergenicity safety assessment to ensure the reliability of allergenicity assessments for food of the future.

食品安全中的过敏性和蛋白质风险评估正面临着新的挑战。对更健康、更可持续的食品体系的需求导致了生物技术的显著进步、更复杂食品的开发以及替代蛋白质来源的寻找。所有这一切都增加了对安全评估预测方法的压力,而这种方法是根据 90 年代末确定的要求制定的。2022 年,欧洲食品安全局转基因生物专家组发表了一份科学意见,重点关注生物技术新产品过敏性和蛋白质安全性评估所需的发展。在此,我们将进一步阐述该科学意见中描述的主要内容,并优先考虑需要重点关注的发展需求。任何新建议的出发点都需要关注临床相关性,并针对特定风险评估目标开发适用的数据库。此外,必须审查和明确过敏性风险评估的主要目的。国际社会就过敏性风险评估的总体目的达成共识,将加快开发适合目的的方法,其中应更好地明确暴露的作用。考虑到过去 25 年取得的经验以及生物技术、过敏症和风险评估领域的最新科学发展,现在是修订和改进过敏性安全评估的时候了,以确保未来食品过敏性评估的可靠性。
{"title":"Research gaps and future needs for allergen prediction in food safety.","authors":"A Fernandez, E Danisman, M Taheri Boroujerdi, S Kazemi, F J Moreno, M M Epstein","doi":"10.3389/falgy.2024.1297547","DOIUrl":"10.3389/falgy.2024.1297547","url":null,"abstract":"<p><p>The allergenicity and protein risk assessments in food safety are facing new challenges. Demands for healthier and more sustainable food systems have led to significant advances in biotechnology, the development of more complex foods, and the search for alternative protein sources. All this has increased the pressure on the safety assessment prediction approaches anchored into requirements defined in the late 90's. In 2022, the EFSA's Panel on Genetically Modified Organisms published a scientific opinion focusing on the developments needed for allergenicity and protein safety assessments of new products derived from biotechnology. Here, we further elaborate on the main elements described in this scientific opinion and prioritize those development needs requiring critical attention. The starting point of any new recommendation would require a focus on clinical relevance and the development of a fit-for-purpose database targeted for specific risk assessment goals. Furthermore, it is imperative to review and clarify the main purpose of the allergenicity risk assessment. An internationally agreed consensus on the overall purpose of allergenicity risk assessment will accelerate the development of fit-for-purpose methodologies, where the role of exposure should be better clarified. Considering the experience gained over the last 25 years and recent scientific developments in the fields of biotechnology, allergy, and risk assessment, it is time to revise and improve the allergenicity safety assessment to ensure the reliability of allergenicity assessments for food of the future.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"5 ","pages":"1297547"},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911423/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140029698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1-allergic asthma. 哮喘前期:预防和改变疾病的有用概念?EUFOREA论文。第一部分:过敏性哮喘。
Q2 ALLERGY Pub Date : 2024-01-30 eCollection Date: 2023-01-01 DOI: 10.3389/falgy.2023.1291185
G K Scadding, M McDonald, V Backer, G Scadding, M Bernal-Sprekelsen, D M Conti, E De Corso, Z Diamant, C Gray, C Hopkins, M Jesenak, P Johansen, J Kappen, J Mullol, D Price, S Quirce, S Reitsma, S Salmi, B Senior, J P Thyssen, U Wahn, P W Hellings

Asthma, which affects some 300 million people worldwide and caused 455,000 deaths in 2019, is a significant burden to suffers and to society. It is the most common chronic disease in children and represents one of the major causes for years lived with disability. Significant efforts are made by organizations such as WHO in improving the diagnosis, treatment and monitoring of asthma. However asthma prevention has been less studied. Currently there is a concept of pre- diabetes which allows a reduction in full blown diabetes if diet and exercise are undertaken. Similar predictive states are found in Alzheimer's and Parkinson's diseases. In this paper we explore the possibilities for asthma prevention, both at population level and also investigate the possibility of defining a state of pre-asthma, in which intensive treatment could reduce progression to asthma. Since asthma is a heterogeneous condition, this paper is concerned with allergic asthma. A subsequent one will deal with late onset eosinophilic asthma.

哮喘影响着全球约 3 亿人,2019 年导致 45.5 万人死亡,给患者和社会造成了沉重负担。它是儿童最常见的慢性疾病,也是造成残疾的主要原因之一。世界卫生组织等组织在改善哮喘的诊断、治疗和监测方面做出了巨大努力。然而,对哮喘预防的研究较少。目前有一种糖尿病前期的概念,如果饮食和运动得当,可以减少糖尿病的发生。在阿尔茨海默氏症和帕金森氏症中也发现了类似的预测状态。在本文中,我们探讨了在人群水平上预防哮喘的可能性,还研究了定义哮喘前期状态的可能性,在这种状态下,强化治疗可以减少哮喘的发展。由于哮喘是一种异质性疾病,本文主要讨论过敏性哮喘。下一篇论文将讨论晚发型嗜酸性粒细胞哮喘。
{"title":"Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1-allergic asthma.","authors":"G K Scadding, M McDonald, V Backer, G Scadding, M Bernal-Sprekelsen, D M Conti, E De Corso, Z Diamant, C Gray, C Hopkins, M Jesenak, P Johansen, J Kappen, J Mullol, D Price, S Quirce, S Reitsma, S Salmi, B Senior, J P Thyssen, U Wahn, P W Hellings","doi":"10.3389/falgy.2023.1291185","DOIUrl":"10.3389/falgy.2023.1291185","url":null,"abstract":"<p><p>Asthma, which affects some 300 million people worldwide and caused 455,000 deaths in 2019, is a significant burden to suffers and to society. It is the most common chronic disease in children and represents one of the major causes for years lived with disability. Significant efforts are made by organizations such as WHO in improving the diagnosis, treatment and monitoring of asthma. However asthma prevention has been less studied. Currently there is a concept of pre- diabetes which allows a reduction in full blown diabetes if diet and exercise are undertaken. Similar predictive states are found in Alzheimer's and Parkinson's diseases. In this paper we explore the possibilities for asthma prevention, both at population level and also investigate the possibility of defining a state of pre-asthma, in which intensive treatment could reduce progression to asthma. Since asthma is a heterogeneous condition, this paper is concerned with allergic asthma. A subsequent one will deal with late onset eosinophilic asthma.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"4 ","pages":"1291185"},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10863454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139731215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Approach for delabeling beta-lactam allergy in children. 更正:儿童对β-内酰胺过敏的脱标方法。
Q2 ALLERGY Pub Date : 2024-01-12 eCollection Date: 2023-01-01 DOI: 10.3389/falgy.2023.1361973
R Sáenz de Santa María, G Bogas, M Labella, A Ariza, M Salas, I Doña, M J Torres

[This corrects the article DOI: 10.3389/falgy.2023.1298335.].

[此处更正了文章 DOI:10.3389/falgy.2023.1298335]。
{"title":"Corrigendum: Approach for delabeling beta-lactam allergy in children.","authors":"R Sáenz de Santa María, G Bogas, M Labella, A Ariza, M Salas, I Doña, M J Torres","doi":"10.3389/falgy.2023.1361973","DOIUrl":"10.3389/falgy.2023.1361973","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/falgy.2023.1298335.].</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"4 ","pages":"1361973"},"PeriodicalIF":0.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10811266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Depressive symptoms are related to asthma control but not self-management among rural adolescents. 抑郁症状与哮喘控制有关,但与农村青少年的自我管理无关。
IF 3.3 Q2 ALLERGY Pub Date : 2024-01-11 eCollection Date: 2023-01-01 DOI: 10.3389/falgy.2023.1271791
Neha B Patel, Amarilis Céspedes, Jianfang Liu, Jean-Marie Bruzzese

Background: Depression, a relevant comorbidity with asthma, has been reported to be associated with asthma morbidity. Asthma self-management is essential to asthma control and may be negatively impacted by depression. We examined these associations in rural adolescents, a group with relatively high asthma morbidity and depressive symptoms, a population often ignored in asthma research.

Methods: We used baseline data from a randomized trial of an asthma intervention for adolescents in rural South Carolina (n = 197). Adolescents completed the Center for Epidemiological Studies-Depression (CES-D), three indices of asthma self-management (the Asthma Prevention Index, the Asthma Management Index and the Asthma Self-Efficacy Index), and the Asthma Control Test (ACT). Poisson and linear regression tested associations between depression, self-management, and asthma control. The models controlled for demographic variables and included school as a fixed effect.

Results: Most participants (mean age = 16.3 ± 1.2 years) self-identified as female (68.5%) and Black (62.43%). The mean CES-D score was 19.7 ± 10.3, with 61.4% of participants at risk for depression. The depressive symptoms were significantly related to asthma control [β = -0.085, 95% confidence interval (CI) = -0.14 to -0.03] but not to prevention [relative risk (RR) = 1.00, 95% CI = 0.99-1.01], management (RR = 1.00, 95% CI = 0.99-1.01), or self-efficacy (β = -0.002, 95% CI = -0.01 to 0.01).

Conclusions: In this sample of rural adolescents, as depressive symptoms increased, asthma control declined. Depressive symptoms were not associated with asthma self-management, suggesting that the aspects of self-management we assessed are not an avenue by which depression impacts asthma control. Additional research is needed to further understand the relationship between depressive symptoms, asthma self-management, and control.

背景:抑郁症是哮喘的一种相关合并症,据报道与哮喘发病率有关。哮喘自我管理对哮喘控制至关重要,而抑郁症可能会对哮喘自我管理产生负面影响。农村青少年是哮喘发病率和抑郁症状相对较高的群体,在哮喘研究中往往被忽视:我们使用了南卡罗来纳州农村青少年哮喘干预随机试验的基线数据(n = 197)。青少年填写了流行病学研究中心抑郁(CES-D)、哮喘自我管理的三个指数(哮喘预防指数、哮喘管理指数和哮喘自我效能指数)以及哮喘控制测试(ACT)。泊松回归和线性回归测试了抑郁、自我管理和哮喘控制之间的关联。这些模型控制了人口统计学变量,并将学校作为固定效应:大多数参与者(平均年龄 = 16.3 ± 1.2 岁)自我认同为女性(68.5%)和黑人(62.43%)。平均 CES-D 得分为 19.7 ± 10.3,61.4% 的参与者有抑郁风险。抑郁症状与哮喘控制明显相关[β = -0.085,95% 置信区间 (CI) = -0.14 to -0.03],但与预防[相对风险 (RR) = 1.00,95% CI = 0.99-1.01]、管理(RR = 1.00,95% CI = 0.99-1.01)或自我效能(β = -0.002,95% CI = -0.01 to 0.01)无关:在这一农村青少年样本中,随着抑郁症状的增加,哮喘控制率也在下降。抑郁症状与哮喘自我管理无关,这表明我们评估的自我管理方面并不是抑郁症影响哮喘控制的途径。要进一步了解抑郁症状、哮喘自我管理和控制之间的关系,还需要进行更多的研究。
{"title":"Depressive symptoms are related to asthma control but not self-management among rural adolescents.","authors":"Neha B Patel, Amarilis Céspedes, Jianfang Liu, Jean-Marie Bruzzese","doi":"10.3389/falgy.2023.1271791","DOIUrl":"10.3389/falgy.2023.1271791","url":null,"abstract":"<p><strong>Background: </strong>Depression, a relevant comorbidity with asthma, has been reported to be associated with asthma morbidity. Asthma self-management is essential to asthma control and may be negatively impacted by depression. We examined these associations in rural adolescents, a group with relatively high asthma morbidity and depressive symptoms, a population often ignored in asthma research.</p><p><strong>Methods: </strong>We used baseline data from a randomized trial of an asthma intervention for adolescents in rural South Carolina (<i>n </i>= 197). Adolescents completed the Center for Epidemiological Studies-Depression (CES-D), three indices of asthma self-management (the Asthma Prevention Index, the Asthma Management Index and the Asthma Self-Efficacy Index), and the Asthma Control Test (ACT). Poisson and linear regression tested associations between depression, self-management, and asthma control. The models controlled for demographic variables and included school as a fixed effect.</p><p><strong>Results: </strong>Most participants (mean age = 16.3 ± 1.2 years) self-identified as female (68.5%) and Black (62.43%). The mean CES-D score was 19.7 ± 10.3, with 61.4% of participants at risk for depression. The depressive symptoms were significantly related to asthma control [<i>β </i>= -0.085, 95% confidence interval (CI) = -0.14 to -0.03] but not to prevention [relative risk (RR) = 1.00, 95% CI = 0.99-1.01], management (RR = 1.00, 95% CI = 0.99-1.01), or self-efficacy (<i>β</i> = -0.002, 95% CI = -0.01 to 0.01).</p><p><strong>Conclusions: </strong>In this sample of rural adolescents, as depressive symptoms increased, asthma control declined. Depressive symptoms were not associated with asthma self-management, suggesting that the aspects of self-management we assessed are not an avenue by which depression impacts asthma control. Additional research is needed to further understand the relationship between depressive symptoms, asthma self-management, and control.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"4 ","pages":"1271791"},"PeriodicalIF":3.3,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pilot study on the use of basophil activation tests and skin tests for the prevention of allergic transfusion reactions 关于使用嗜碱性粒细胞活化试验和皮试预防过敏性输血反应的试点研究
Q2 ALLERGY Pub Date : 2024-01-08 DOI: 10.3389/falgy.2023.1328227
Philippe Akiki, L. Dedeken, Alina Ferster, Virginie Doyen, Gwendy Dupire, Carole Nagant, Julie Smet, Nathalie Ghorra, Isabelle Ruth, Maïlis Lauwers, Valery Daubie, Francis Corazza, H. El Kenz
Management of severe allergic transfusion reactions (ATR) is challenging. In this study, we investigate the usefulness of skin tests and basophil activation tests (BAT) in chronically transfused patients for the prevention of future ATR.BAT and skin tests were carried with the supernatant of red blood cell (RBC) units for a sickle-cell disease patient under chronic exchange transfusion who has presented a severe ATR, in order to prevent potential future ATR. If the results for both BAT and skin tests were negative, the RBC units could be transfused to the patient. If either one of the results was positive, the tested RBC unit was discarded for the patient.192 RBC units were tested with both tests. The level of results concordance between the two tests was 95%. Out of the 169 negative units with both tests, 118 units were transfused to the patient for which he presented no ATR.In our study, combining both BAT and skin tests was associated with a good negative predictive value since we were able to safely transfuse our patient. Further studies are still necessary to confirm this result but this pilot study indicates that skin tests and BAT might help prevent ATR. When BAT is not available, skin tests may also be useful in preventing ATR.
严重过敏性输血反应(ATR)的处理极具挑战性。在这项研究中,我们调查了皮肤测试和嗜碱性粒细胞活化测试(BAT)在长期输血患者中的应用,以预防未来的输血过敏反应。如果 BAT 和皮试结果均为阴性,则可向患者输注红细胞单位。如果其中一项检测结果呈阳性,则该患者将放弃接受检测的红细胞单位192。两种检测结果的一致性为 95%。在我们的研究中,结合 BAT 和皮试具有良好的阴性预测价值,因为我们能够安全地为患者输血。仍需进一步研究来证实这一结果,但这项试点研究表明,皮试和 BAT 可能有助于预防 ATR。在无法使用 BAT 的情况下,皮试也可能有助于预防 ATR。
{"title":"Pilot study on the use of basophil activation tests and skin tests for the prevention of allergic transfusion reactions","authors":"Philippe Akiki, L. Dedeken, Alina Ferster, Virginie Doyen, Gwendy Dupire, Carole Nagant, Julie Smet, Nathalie Ghorra, Isabelle Ruth, Maïlis Lauwers, Valery Daubie, Francis Corazza, H. El Kenz","doi":"10.3389/falgy.2023.1328227","DOIUrl":"https://doi.org/10.3389/falgy.2023.1328227","url":null,"abstract":"Management of severe allergic transfusion reactions (ATR) is challenging. In this study, we investigate the usefulness of skin tests and basophil activation tests (BAT) in chronically transfused patients for the prevention of future ATR.BAT and skin tests were carried with the supernatant of red blood cell (RBC) units for a sickle-cell disease patient under chronic exchange transfusion who has presented a severe ATR, in order to prevent potential future ATR. If the results for both BAT and skin tests were negative, the RBC units could be transfused to the patient. If either one of the results was positive, the tested RBC unit was discarded for the patient.192 RBC units were tested with both tests. The level of results concordance between the two tests was 95%. Out of the 169 negative units with both tests, 118 units were transfused to the patient for which he presented no ATR.In our study, combining both BAT and skin tests was associated with a good negative predictive value since we were able to safely transfuse our patient. Further studies are still necessary to confirm this result but this pilot study indicates that skin tests and BAT might help prevent ATR. When BAT is not available, skin tests may also be useful in preventing ATR.","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"12 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139445155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: IgE mediated and non IgE mediated cow’s milk protein allergy 社论:IgE 介导和非 IgE 介导的牛奶蛋白过敏症
Q2 ALLERGY Pub Date : 2024-01-08 DOI: 10.3389/falgy.2023.1354711
Rita Nocerino
{"title":"Editorial: IgE mediated and non IgE mediated cow’s milk protein allergy","authors":"Rita Nocerino","doi":"10.3389/falgy.2023.1354711","DOIUrl":"https://doi.org/10.3389/falgy.2023.1354711","url":null,"abstract":"","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"47 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139446146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1